Unknown

Dataset Information

0

OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.


ABSTRACT: There is an urgent need for new, potent antituberculosis (anti-TB) drugs with novel mechanisms of action that can be included in new regimens to shorten the treatment period for TB. After screening a library of carbostyrils, we optimized 3,4-dihydrocarbostyril derivatives and identified OPC-167832 as having potent antituberculosis activity. The MICs of the compound for Mycobacterium tuberculosis ranged from 0.00024 to 0.002??g/ml. It had bactericidal activity against both growing and intracellular bacilli, and the frequency of spontaneous resistance for M. tuberculosis H37Rv was less than 1.91?×?10-7 It did not show antagonistic effects with other anti-TB agents in an in vitro checkerboard assay. Whole-genome and targeted sequencing of isolates resistant to OPC-167832 identified decaprenylphosphoryl-?-d-ribose 2'-oxidase (DprE1), an essential enzyme for cell wall biosynthesis, as the target of the compound, and further studies demonstrated inhibition of DprE1 enzymatic activity by OPC-167832. In a mouse model of chronic TB, OPC-167832 showed potent bactericidal activities starting at a dose of 0.625?mg/kg of body weight. Further, it exhibited significant combination effects in 2-drug combinations with delamanid, bedaquiline, or levofloxacin. Finally, 3- or 4-drug regimens comprised of delamanid and OPC-167832 as the core along with bedaquiline, moxifloxacin, or linezolid showed efficacy in reducing the bacterial burden and preventing relapse superior to that of the standard treatment regimen. In summary, these results suggest that OPC-167832 is a novel and potent anti-TB agent, and regimens containing OPC-167832 and new or repurposed anti-TB drugs may have the potential to shorten the duration of treatment for TB.

SUBMITTER: Hariguchi N 

PROVIDER: S-EPMC7269503 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


There is an urgent need for new, potent antituberculosis (anti-TB) drugs with novel mechanisms of action that can be included in new regimens to shorten the treatment period for TB. After screening a library of carbostyrils, we optimized 3,4-dihydrocarbostyril derivatives and identified OPC-167832 as having potent antituberculosis activity. The MICs of the compound for <i>Mycobacterium tuberculosis</i> ranged from 0.00024 to 0.002 μg/ml. It had bactericidal activity against both growing and intr  ...[more]

Similar Datasets

| S-EPMC8154581 | biostudies-literature
| S-EPMC7126670 | biostudies-literature
| S-EPMC9233935 | biostudies-literature
| S-EPMC6792157 | biostudies-literature
| S-EPMC2742177 | biostudies-literature
| S-EPMC8602566 | biostudies-literature
| S-EPMC8072539 | biostudies-literature
| S-EPMC4674098 | biostudies-literature
2012-07-19 | E-GEOD-38008 | biostudies-arrayexpress
| S-EPMC10581193 | biostudies-literature